'김갑성' 기자의 전체기사
-
Sunshine Lake Pharma Co., Ltd. (06887.HK) Completes Listing…
GUANGZHOU, China, Aug. 5, 2025 -- Sunshine Lake Pharma Co., Ltd. (06887.HK) announced that the company will officially list on the Hong Kong Stock Exchange on August 7th. Through this integration, the company has effectively combined its expertise in drug R&D with the mature nationwide sales network resources of Sunshine Lake Pharma Co., Ltd. This forms an R&D-manufacturing-sales closed loop to accelerate global operations, thereby driving value reshaping and laying a more solid foundation for future sustainable development, including international expansion. This year, propell
- 김갑성 기자
- 2025-08-05 15:34
-
Chugai Pharma Taiwan Honored at the AREA 2025 for its Social E…
BANGKOK, Aug. 4, 2025 -- Chugai Pharma Taiwan (CPT), a subsidiary of Chugai Pharmaceutical Co., Ltd. in Japan, has been recognized in both the Social Empowerment and Green Leadership categories at the Asia Responsible Enterprise Awards (AREA) 2025. These recognitions highlight the company's exceptional efforts in driving community impact and environmental sustainability through healthcare-focused innovation and compassion. In the Social Empowerment category, CPT was recognized for its heartfelt and impactful charitable initiatives. Through its annual charity cycling event, CPT not only
- 김갑성 기자
- 2025-08-05 13:02
-
TSH Biopharm Honored for Social Empowerment and Green Le…
BANGKOK, Aug. 4, 2025 -- TSH Biopharm Corporation Ltd. has been recognized with dual honors at the Asia Responsible Enterprise Awards 2025, receiving accolades for the Green Leadership and Social Empowerment categories. The awards reflect the company's growing influence as a purpose-driven pharmaceutical firm that integrates sustainability and human well-being into its corporate DNA. TSH Biopharm's Green Leadership accolade celebrates its signature initiative, "Sowing with Heart," which redefines the connection between health and the environment. In a pioneering effort, the c
- 김갑성 기자
- 2025-08-05 12:27
-
WuXi XDC Achieves GMP Release of Newly Launched DP3 Facili…
WUXI, China, Aug. 5, 2025 -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the Drug Product 3 ("DP3") facility at the Wuxi site has completed GMP release at the end of July, signifying the company's relentless pursuit of excellence in capacity expansion and business growth. In just 18 months, WuXi XDC has rapidly completed the advanced design, construction, equipment qualification, media fill and GMP release of the DP3
- 김갑성 기자
- 2025-08-05 10:13
-
Smart Jelly for Smart Aging: Chula's High-Protein Pudding Take…
BANGKOK, Aug. 5, 2025 -- Chulalongkorn University's "High-Protein Jelly Pudding with Modified Texture for the Elderly with Swallowing Difficulties," developed by Asst. Prof. Dr. Varanya Techasukthavorn and a team from the Faculty of Allied Health Sciences, won a bronze medal in Geneva, along with a special award from Malaysia. Striking with banana and strawberry flavors, the jelly pudding is easy to consume and provides a high protein content of 7-8 grams per cup to strengthen muscles. It's suitable for the elderly, patients, and those who need additional protein. The team is prepar
- 김갑성 기자
- 2025-08-05 10:00
-
Innovent Receives U.S. FDA Approval for IND Application of Oral G…
SAN FRANCISCO and SUZHOU, China, Aug. 5, 2025 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial of IBI3032, the company's novel oral GLP-1R agonist. IBI3032 is an orally administered small-molecule
- 김갑성 기자
- 2025-08-05 08:00
-
LA ROCHE-POSAY AND GLOBAL SKIN HEALTH EXPERTS UNITE TO WARN A…
PARIS, Aug. 5, 2025 -- A viral TikTok challenge known as "Burn Lines" or "Sunburn Tattoos" is gaining alarming traction among teenagers and young adults worldwide. The trend, which involves placing tape or stencils on the skin to intentionally burn patterned tan lines, has sparked widespread concern among global health experts. France's Minister of Health stated recently: "For a few seconds of buzz on social media, young people are destroying their skin cells for life. We only get one skin." LA ROCHE-POSAY REAFFIRMS ITS LONGSTANDING COMMITME
- 김갑성 기자
- 2025-08-05 05:15
-
Gates Foundation Announces Catalytic Funding to Spark Ne…
[ 메디채널 김갑성 기자 ] Investments Through 2030 to Catalyze Innovation in Maternal, Menstrual, Gynecological, and Sexual Health for Women Globally SEATTLE, Aug. 4, 2025 -- The Gates Foundation today announced a $2.5 billion commitment through 2030 to accelerate research and development (R&D) focused exclusively on women's health. It will support the advancement of more than 40 innovations in five critical, chronically underfunded areas—particularly those affecting women in low- and middle-income countries. "For too long, women have suffered from health conditions that are mi
- 김갑성 기자
- 2025-08-04 22:00
-
Pulsecare Medical Announces NMPA Approval of NxPFA™, the…
SHENZHEN, China, Aug. 4, 2025 -- Pulsecare Medical, a pioneer in cardiovascular intervention technologies, announced that its innovative NxPFA™ nanosecond pulsed field ablation (ns-PFA) systemhas received marketing approval from China's National Medical Products Administration (NMPA). As the world's first third-generation ns-PFA system utilizing high-voltage nanosecond pulses for pulmonary vein isolation (PVI) in atrial fibrillation (AF) treatment, this breakthrough marks the dawn of the PFA 3.0 era and represents the innovative capabilities of Pulsecare Medical in cardiovascular multimodal t
- 김갑성 기자
- 2025-08-04 21:30
-
Minaris Advanced Therapies Opens New State-of-the-Art GMP…
MUNICH, Aug. 4, 2025 -- Minaris Advanced Therapies, a leading global contract development and manufacturing organization and testing provider, has announced the opening of its new GMP manufacturing facility in Munich, Germany. The facility, located in Taufkirchen, strengthens Minaris' global manufacturing network and reinforces its position as a trusted partner in advancing cutting-edge therapies from concept to commercialization. Minaris' new facility builds on over 10 years of experience in both the clinical and commercial manufacture of advanced therapies.
- 김갑성 기자
- 2025-08-04 21:00
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-10-24_FRI
- Euroclear builds on strong momentum in Q3 2025 16:30
- Light and Moon Together: CHD Celebrates Mid-Autumn Festival Across Southeast Asia 16:03
- Light and Moon Together: CHD Celebrates Mid-Autumn Festival Across Southeast Asia 16:02
- Light and Moon Together: China Huadian Corporation (CHD) Celebrates Mid-Autumn Festival Across Southeast Asia 15:57
- GAC Supplies Official Fleet and 24/7 Support for the 15th National Games in Hong Kong and Macao 15:51
- NTT DOCOMO BUSINESS and NTT Com Asia Launch "APN InterLink" Service in Hong Kong 15:43
- ASEAN-China (Beijing Municipal Administrative Center) Trade and Investment Promotion Conference in Beijing 15:29
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 10월 24일 18시 00분